1. Home
  2. VERU vs GIFT Comparison

VERU vs GIFT Comparison

Compare VERU & GIFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Veru Inc.

VERU

Veru Inc.

HOLD

Current Price

$2.33

Market Cap

40.9M

Sector

Health Care

ML Signal

HOLD

Logo RDE Inc.

GIFT

RDE Inc.

HOLD

Current Price

$0.91

Market Cap

39.0M

ML Signal

HOLD

Company Overview

Basic Information
Metric
VERU
GIFT
Founded
1971
1999
Country
United States
United States
Employees
N/A
40
Industry
Biotechnology: Pharmaceutical Preparations
Catalog/Specialty Distribution
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
40.9M
39.0M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
VERU
GIFT
Price
$2.33
$0.91
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$22.50
N/A
AVG Volume (30 Days)
53.4K
42.6K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$16,296,958.00
N/A
Revenue This Year
N/A
$8.19
Revenue Next Year
N/A
$10.30
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.36
$0.73
52 Week High
$4.59
$1.94

Technical Indicators

Market Signals
Indicator
VERU
GIFT
Relative Strength Index (RSI) 56.93 42.07
Support Level $2.12 $0.79
Resistance Level $2.67 $1.15
Average True Range (ATR) 0.12 0.09
MACD 0.01 -0.01
Stochastic Oscillator 96.67 33.01

Price Performance

Historical Comparison
VERU
GIFT

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

About GIFT RDE Inc.

Giftify Inc operates in the incentive and rewards industry with a focus on retail, dining, and entertainment experiences, as the owner and operator of digital platforms, CardCash.com, Restaurant.com, and Takeout7.com. CardCash.com is a secondary gift card exchange platform, allowing consumers and retailers to buy and sell gift cards at various scales from several retailers; Restaurant.com is a restaurant-focused digital deals brand, connecting digital consumers and businesses by offering dining, retail, and entertainment deal options at several restaurants and retailers; and Takeout7 is a restaurant technology company offering online ordering solutions and AI-powered digital marketing services. Giftify has one segment, the sale of gift cards and discount certificates to its customers.

Share on Social Networks: